9.03

1.85% -0.17

After Hours: 9.03

Biohaven Ltd (BHVN)

Overview News Price History Option Chain Financials Why BHVN Down? Discussions Forecast

Biohaven Ltd stock is traded at $9.03, with a volume of 2.37M. It is down -1.85% in the last 24 hours and down -10.77% over the past month. Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Previous Close:

$9.20

Open:

$9.1

24h Volume:

2.37M

Relative Volume:

1.12

Market Cap:

$1.36B

Revenue:

Net Income/Loss:

$-738.82M

P/E Ratio:

-1.2974

EPS:

-6.9602

Net Cash Flow:

$-610.15M

1W Performance:

-10.06%

1M Performance:

-10.77%

6M Performance:

+11.76%

1Y Performance:

-53.72%

1-Day Range:

$8.88

$9.1275

1-Week Range:

$8.85

$10.11

52-Week Range:

$7.48

$20.09

Biohaven Ltd Stock (BHVN) Company Profile

Name

Biohaven Ltd

Sector

Healthcare (1106)

Industry

Biotechnology (616)

Phone

203-404-0410

Address

215 CHURCH STREET, NEW HAVEN, CT

Employee

274

Twitter

@biohavenpharma

Next Earnings Date

2026-05-11

Latest SEC Filings

BHVN's Discussions on Twitter

Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BHVN Biohaven Ltd	9.03	1.39B	0	-738.82M	-610.15M	-6.9602
VRTX Vertex Pharmaceuticals Inc	453.06	113.78B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	719.88	75.84B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	802.70	50.55B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.48	38.99B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	316.55	32.69B	5.76B	514.49M	1.10B	4.4813

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	Canaccord Genuity	Buy
Feb-06-26	Initiated	Goldman	Buy
Jan-21-26	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Dec-03-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-26-25	Downgrade	UBS	Buy → Neutral
Nov-06-25	Downgrade	Bernstein	Outperform → Mkt Perform
Nov-05-25	Downgrade	BofA Securities	Buy → Neutral
Sep-17-25	Initiated	Citigroup	Buy
Sep-03-25	Initiated	Raymond James	Strong Buy
May-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-11-25	Initiated	Deutsche Bank	Buy
Sep-16-24	Initiated	Jefferies	Buy
Sep-04-24	Initiated	Bernstein	Outperform
Jul-24-24	Initiated	Morgan Stanley	Overweight
Feb-16-24	Initiated	RBC Capital Mkts	Outperform
Feb-06-24	Initiated	UBS	Buy
Dec-22-23	Initiated	H.C. Wainwright	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Jan-24-23	Initiated	SVB Securities	Outperform
Jan-04-23	Initiated	JP Morgan	Overweight
Dec-02-22	Initiated	BTIG Research	Buy
Oct-26-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Oct-12-22	Initiated	Piper Sandler	Overweight
Aug-19-22	Downgrade	Piper Sandler	Overweight → Neutral
Aug-08-22	Downgrade	Wedbush	Outperform → Neutral
May-11-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-10-21	Downgrade	UBS	Buy → Neutral
Aug-03-21	Reiterated	Canaccord Genuity	Buy
Mar-11-21	Initiated	UBS	Buy
Dec-15-20	Initiated	H.C. Wainwright	Buy
Apr-17-20	Initiated	Cowen	Outperform
Feb-10-20	Downgrade	Oppenheimer	Outperform → Perform
Feb-06-20	Initiated	Mizuho	Buy
Nov-22-19	Initiated	Wedbush	Outperform
Jun-25-19	Reiterated	Canaccord Genuity	Buy
May-06-19	Initiated	Goldman	Buy
Apr-09-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-04-19	Reiterated	Needham	Buy
Jul-03-18	Reiterated	Needham	Buy
Jul-02-18	Reiterated	Needham	Buy
Apr-05-18	Downgrade	Barclays	Overweight → Equal Weight
Feb-22-18	Reiterated	Canaccord Genuity	Buy
Dec-15-17	Initiated	Canaccord Genuity	Buy
Oct-03-17	Reiterated	Needham	Buy

View All

Biohaven Ltd Stock (BHVN) Latest News

May 13, 2026

Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $18 - Moomoo

May 13, 2026

Morgan Stanley Cuts Price Target on Biohaven to $18 From $21, Keeps Overweight Rating - Moomoo

May 13, 2026

TradingKey - TradingKey

May 13, 2026

Biohaven Ltd. Stock 12‑Month Price Target Cut to $22.19, Implies 141% Upside - TradingView

May 13, 2026

May 12, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 12, 2026

H.C. Wainwright reiterates Biohaven stock rating ahead of trial By Investing.com - Investing.com South Africa

May 12, 2026

Biohaven (BHVN) Valuation Check After Q1 Results And New Shelf Registration - simplywall.st

May 12, 2026

H.C. Wainwright reiterates Biohaven stock rating ahead of trial - Investing.com

May 12, 2026

Biohaven: Hold Rating Reiterated as Clinical and Competitive Uncertainties Persist; Price Target Maintained at $10 - TipRanks

May 12, 2026

H.C. Wainwright Maintains Biohaven(BHVN.US) With Hold Rating, Maintains Target Price $10 - Moomoo

May 12, 2026

May 11, 2026

How Biohaven Ltd. (BHVN) Affects Rotational Strategy Timing - Stock Traders Daily

May 11, 2026

May 10, 2026

BHVN Stock Price Prediction 2025-2026 | Biohaven Pharmaceutical Holding Co Ltd Forecast | 24/7 Wall St. - 24/7 Wall St.

May 10, 2026

May 09, 2026

Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf RegistrationWhat's Changed - Yahoo Finance

May 06, 2026

Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures - TipRanks

May 06, 2026

May 05, 2026

Biohaven Expands At-The-Market Equity Offering Program - TipRanks

May 05, 2026

Biohaven (NYSE: BHVN) adds $350.0 million at-the-market share program - Stock Titan

May 05, 2026